Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q86W47
UPID:
KCMB4_HUMAN
Alternative names:
BK channel subunit beta-4; Calcium-activated potassium channel, subfamily M subunit beta-4; Charybdotoxin receptor subunit beta-4; K(VCA)beta-4; Maxi K channel subunit beta-4; Slo-beta-4
Alternative UPACC:
Q86W47; Q8IVR3; Q9NPA4; Q9P0G5
Background:
The Calcium-activated potassium channel subunit beta-4, known by alternative names such as BK channel subunit beta-4 and Maxi K channel subunit beta-4, plays a crucial role in modulating the calcium sensitivity and gating kinetics of the KCNMA1 channel. This regulatory subunit contributes to the channel's diversity by altering its gating kinetics and calcium sensitivity, making it resistant to charybdotoxin toxin concentrations.
Therapeutic significance:
Understanding the role of Calcium-activated potassium channel subunit beta-4 could open doors to potential therapeutic strategies.